TABLE 5.
Clinical cure rates at TOC visit for patients in ME population with S. aureus infections
| Cause of infection | Cure rate (no. of patients cured/total no. of patients [%])
|
95% CI of difference | |
|---|---|---|---|
| Ceftobiprole group | Vancomycin group | ||
| All S. aureus isolates | 177/187 (94.6) | 162/172 (94.2) | −0.4 (−4.3, 5.2) |
| MSSA | 121/126 (96.0) | 108/112 (96.4) | −0.4 (−5.2, 4.4) |
| MRSA | 56/61 (91.8) | 54/60 (90.0) | 1.8 (−8.4, 12.1) |
| PVL positive + MRSA | 27/29 (93.1) | 22/26 (84.6) | |
| MRSA and CRPa >50 mg/dl | 20/23 (86.9) | 21/24 (87.5) | |
| MRSA infections extending to fascia or muscle | 19/21 (90.5) | 18/21 (85.7) | |
a
CRP, C-reactive protein.